On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: a
about
Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDLHighlights of the year in JACC 2012Association of lipid profiles and the ratios with arterial stiffness in middle-aged and elderly Chinese.Update on the NCEP ATP-III emerging cardiometabolic risk factors.Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) studyDifferential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures.Intensive Statin Therapy in NSTE-ACS Patients Undergoing PCI: Clinical and Biochemical EffectsAtherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating RosStatin Dose and the Risk of Intracerebral Hemorrhage: A Population-Based Longitudinal Study in Taiwan.Dyslipidemia in obesity: mechanisms and potential targetsAssociation of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapyHigh-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapyLipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).Evidence-based goals in LDL-C reduction.HDL cholesterol and cardiovascular outcomes: what is the evidence?Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins.Risk prediction with triglycerides in patients with stable coronary disease on statin treatment.
P2860
Q26801507-961A5B39-2DD8-424E-BB6C-694B56B94284Q26865608-76C5DD44-B643-4D32-B0F1-3F2BCA41DBB7Q34522939-6951F559-DD98-4D73-AB37-7749F12628DAQ34811590-1FDA555C-8B2A-467E-A455-F25FE05046B5Q35917143-9A0AA3AC-0B22-49B0-9B62-F5AA7794A018Q36199734-E975B2DA-6198-40D8-875C-01001684E9F6Q36334449-045B31CD-6247-40FD-86BC-57DDFC84FC47Q36359891-267D9E67-AABF-4D22-854D-F3B90D6390F9Q36721658-0B2AA678-8F7E-49D8-80F1-9A06E316A96FQ36994072-E9720D98-E594-40B2-8E9B-5BD794F4B95DQ37031309-D75FFD39-5EFE-4EFF-BC96-6ECAAE7FAB57Q37115301-56C24054-5CE4-4BD2-B637-600E017AC461Q37254454-FDB3DEB3-9271-46E3-88F1-60AC4C902FE3Q37623853-396C064A-62C0-486E-B4AD-80BBD5635657Q37714588-7BDBB2CE-98CC-4E59-ACFF-6871D3900707Q38082718-E1E719FE-A85F-4865-B599-C5B67C755D7CQ38175934-6EABEB34-1B47-47EB-8343-C25C8DBDF1B9Q38373507-35A5B1E3-1BF2-4679-9E9D-D3C1AE15D869Q38377434-F4D17371-B50D-498A-B5F8-C585F9E1566AQ49736271-CB677A7D-FC82-4980-947A-AE2C727072ECQ51319217-23E0CAC3-A729-4372-86A9-A0576F390211
P2860
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: a
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
On-treatment non-high-density ...... se of statins in prevention: a
@ast
On-treatment non-high-density ...... se of statins in prevention: a
@en
type
label
On-treatment non-high-density ...... se of statins in prevention: a
@ast
On-treatment non-high-density ...... se of statins in prevention: a
@en
prefLabel
On-treatment non-high-density ...... se of statins in prevention: a
@ast
On-treatment non-high-density ...... se of statins in prevention: a
@en
P2093
P2860
P921
P1476
On-treatment non-high-density ...... se of statins in prevention: a
@en
P2093
John J P Kastelein
Paul M Ridker
Robert J Glynn
S Matthijs Boekholdt
Samia Mora
P2860
P304
P356
10.1016/J.JACC.2011.12.035
P407
P577
2012-04-01T00:00:00Z